Australis Partners has acquired 80% of stake in Chile-based vitro diagnostic company Galénica. Financial terms of the transaction were not disclosed.

(Press Release) Australis Partners Fund L.P. (“Australis Partners”) has completed the acquisition of 80% of the shares of Galénica S.A. (“Galénica” or the “Company”). Financial terms of the transaction were not disclosed.

The Company is a leading in vitro diagnostics player in Chile, focused on the import, distribution, commercialization and post-sale services of medical equipment and reagents through its global brand partnerships. The Company has more than 30 years of presence in the Chilean Health System and multinational distribution partnerships related to medical equipment and supplies for clinical diagnosis, blood bank, molecular biology and clinical supplies, quality control and biotechnology. The Company’s main customers are public and private hospitals, universities and medical centers.

Enrique Bascur, Managing Partner of Australis Partners, said: “This is our second investment in the healthcare sector in the region. We are confident of the growth potential and solid fundamentals of this industry in our target countries, considering the current under penetration of healthcare spend in Latin America.”

About Australis Partners

Australis Partners (Advisers), LLC is an independent investment firm that manages private equity funds with a focus on the Pacific Alliance countries of Mexico, Colombia, Peru and Chile. As of October 31st, 2020, Australis Partners has over $500 million of assets under management. For more information, visit www.australispartners.com